3,5-Dinitro-Tyr-OH

CAS# 17360-11-1

3,5-Dinitro-Tyr-OH

Catalog No. BCC3331----Order now to get a substantial discount!

Product Name & Size Price Stock
3,5-Dinitro-Tyr-OH:10g $213.00 In stock
3,5-Dinitro-Tyr-OH:20g $362.00 In stock
3,5-Dinitro-Tyr-OH:50g $852.00 In stock
3,5-Dinitro-Tyr-OH:100g $1491.00 In stock
Related Products

Quality Control of 3,5-Dinitro-Tyr-OH

Number of papers citing our products

Chemical structure

3,5-Dinitro-Tyr-OH

3D structure

Chemical Properties of 3,5-Dinitro-Tyr-OH

Cas No. 17360-11-1 SDF Download SDF
PubChem ID 439948 Appearance Powder
Formula C9H9N3O7 M.Wt 271.2
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
SMILES C1=C(C=C(C(=C1[N+](=O)[O-])O)[N+](=O)[O-])CC(C(=O)O)N
Standard InChIKey SAZOSDSFLRXREA-YFKPBYRVSA-N
Standard InChI InChI=1S/C9H9N3O7/c10-5(9(14)15)1-4-2-6(11(16)17)8(13)7(3-4)12(18)19/h2-3,5,13H,1,10H2,(H,14,15)/t5-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

3,5-Dinitro-Tyr-OH Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

3,5-Dinitro-Tyr-OH Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of 3,5-Dinitro-Tyr-OH

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.6873 mL 18.4366 mL 36.8732 mL 73.7463 mL 92.1829 mL
5 mM 0.7375 mL 3.6873 mL 7.3746 mL 14.7493 mL 18.4366 mL
10 mM 0.3687 mL 1.8437 mL 3.6873 mL 7.3746 mL 9.2183 mL
50 mM 0.0737 mL 0.3687 mL 0.7375 mL 1.4749 mL 1.8437 mL
100 mM 0.0369 mL 0.1844 mL 0.3687 mL 0.7375 mL 0.9218 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on 3,5-Dinitro-Tyr-OH

3,5-Dinitro-Tyr-OH

Featured Products
New Products
 

References on 3,5-Dinitro-Tyr-OH

Evaluation of the (1,3)-beta-D-glucan assay for the diagnosis of neonatal invasive yeast infections.[Pubmed:28371838]

Med Mycol. 2018 Jan 1;56(1):78-87.

Most newborns in the neonatal intensive care unit (NICU) are premature and at risk of invasive fungal infections (IFIs). Invasive yeast infections (IYIs) are the most common fungal infections in this population. These infections are difficult to diagnose because symptoms are nonspecific, and the sensitivity of blood cultures is low. The serum (1,3)-beta-D-glucan (BDG) assay provides a reliable marker for the diagnosis of IFIs in adults with haematological malignancies. We assessed the diagnostic performance of this test in neonatal IYIs and its contribution to the monitoring of antifungal treatment. A retrospective study was performed in the NICU of the French University Hospital of Amiens from February 2012 to February 2014. Forty-seven neonates (33 males, 14 females) with a median gestational age of 30 weeks (IQR: 27-31) and median birth weight of 1200 g (IQR: 968-1700) were included and divided into three groups: 21 control neonates (CTRL), 20 neonates with probable IYI (PB), and six with proven IYI (PV). Median BDG levels were significantly higher in the global IYI group (PB + PV): 149 pg/ml (IQR: 85-364) vs. CTRL group: 39 pg/ml (IQR: 20-94) (P < .001). The optimal cut-off was 106 pg/ml (sensitivity 61.5%; specificity 81%). BDG levels decreased with antifungal treatment. BDG was detectable in cerebrospinal fluid, but the interest of this for diagnostic purposes remains unclear. Our results suggest that the BDG assay may be useful for the early identification of IYIs in neonates and for monitoring antifungal therapy efficacy.

Angiopoietin-like protein 3 and 4 expression 4 and their serum levels in hepatocellular carcinoma.[Pubmed:28371666]

Cytokine. 2017 Aug;96:75-86.

BACKGROUND: Hepatocellular carcinoma (HCC) is the 6th most common cancer and the 3rd leading cause of cancer causing death allover the world. The aim of this research to explore the clinical relevance of blood angiopoietin-like protein-3 (ANGPTL3) and ANGPTL4 expression and their proteins levels as non invasive biomarkers in cirrhotic and HCC patients and their influence on the clinicopathological features of HCC. MATERIAL AND METHODS: This work comprised 200 patients with chronic hepatitis (120 cases complicated with cirrhosis, 80 patients with primary HCC) and 100 controls. circulating ANGPTL3 and ANGPTL4 expression was estimated by real-time polymerase chain reaction (RT-PCR). ANGPTL3 and ANGPTL4 protein levels were determined by enzyme-linked immunosorbent assay (ELISA). RESULTS: The circulating ANGPTL3 and ANGPTL 4 expression was significantly elevated in HCC cases compared to chronic hepatitis patients and controls. There were much more serum ANGPTL3 and ANGPTL4 values in HCC and chronic hepatitis patients as compared to controls, but we couldn't detect this significance between chronic hepatitis and HCC cases as regards ANGPTL4. By Multiple stepwise linear regression analysis, an increased ANGPTL3 expression, alpha-fetoprotein (AFP), serum ANGPTL 3 levels, Child-Pugh grade were significantly assosciatedassociated with increased risk of HCC. Logistic regression analysis revealed that ANGPTL 3 expression and AFP levels were the only pridectorspredictors of HCC (odd's ratio (OR)=8.9; 8.6 respectively, P=0.003). Receiver operator characteristic (ROC) demonsterated that serum ANGPTL3 and ANGPTL4 levels were usufuluseful biomarkers discriminating chronic hepatitis cases from controls (AUC=0.820,0.887, respectively P<0.001). However, they fail to discriminate HCC patients from chronic hepatitis patients (P=0.27,0.12 respectively). Moreover, ANGPTL3 and ANGPTL 4 expression were promising biomarkers discriminating chronic hepatitis cases from controls and those HCC cases from chronic hepatitis patients (P<0.001). Combined ANGPTL3 expression and serum level wasn't useful in discriminating HCC patient from chronic hepatitis (P=0.09). In contrast, combined ANGPTL4 expression and serum level was an useful biomarker discriminating HCC cases from chronic hepatitis. CONCLUSION: ANGPTL3 and ANGPTL 4 expression and serum levels can be promising non invasive biomarkers in diagnosis of chronic hepatitis and HCC especially their expression could be useful in discriminating HCC from chronic hepatitis patients.

Synthesis and study of anti-HIV-1 RT activity of 5-benzoyl-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one derivatives.[Pubmed:28371664]

Bioorg Chem. 2017 Jun;72:74-79.

In the present study, a series of fourteen 5-benzoyl-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one derivatives were designed, synthesized and characterized by appropriate spectral analysis. Further, titled compounds were in-vitro screened against wild HIV-1 RT enzyme using ELISA based colorimetric assay, in which four compounds significantly inhibited the RT activity with IC50

Analysis of Packet-Loss-Induced Distortion in View Synthesis Prediction-Based 3D Video Coding.[Pubmed:28371778]

IEEE Trans Image Process. 2017 Jun;26(6):2781-2796.

View synthesis prediction (VSP) is a crucial coding tool for improving compression efficiency in the next generation 3D video systems. However, VSP is susceptible to catastrophic error propagation when multi-view video plus depth (MVD) data are transmitted over lossy networks. This paper aims at accurately modeling the transmission errors propagated in the inter-view direction caused by VSP. Toward this end, we first study how channel errors gradually propagate along the VSP-based inter-view prediction path. Then, a new recursive model is formulated to estimate the expected end-to-end distortion caused by those channel losses. For the proposed model, the compound impact of the transmission distortions of both the texture video and depth map on the quality of the synthetic reference view is mathematically analyzed. Especially, the expected view synthesis distortion due to depth errors is characterized in the frequency domain using a new approach, which combines the energy densities of the reconstructed texture image and the channel errors. The proposed model also explicitly considers the disparity rounding operation invoked for the sub-pixel precision rendering of the synthesized reference view. Experimental results are presented to demonstrate that the proposed analytic model is capable of effectively modeling the channel-induced distortion for MVD-based 3D video transmission.

Keywords:

3,5-Dinitro-Tyr-OH,17360-11-1,Natural Products,Unusual Amino Acids, buy 3,5-Dinitro-Tyr-OH , 3,5-Dinitro-Tyr-OH supplier , purchase 3,5-Dinitro-Tyr-OH , 3,5-Dinitro-Tyr-OH cost , 3,5-Dinitro-Tyr-OH manufacturer , order 3,5-Dinitro-Tyr-OH , high purity 3,5-Dinitro-Tyr-OH

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: